Literature DB >> 19921253

Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

Michiyuki Hakozaki1, Hiroshi Hojo, Michiko Sato, Takahiro Tajino, Hitoshi Yamada, Shinichi Kikuchi, Masafumi Abe.   

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma. We established a new human MPNST cell line (designated FMS-1) from MPNST of the right brachial plexus of a 69-year-old woman with NF1. The cell line has been maintained for >24 months with >100 passages. FMS-1 cells showed a fibrosarcoma-like or epithelioid pattern in the heterotransplanted tumor, compared with a fascicular growth pattern of short-spindle tumor cells in the primary tumor. Immunophenotypically, FMS-1 cells showed almost the same characteristics as the primary tumor. Cytogenetic and molecular analyses revealed a deletion in exons 5-8 of the p53 gene. Epidermal growth factor receptor (EGFR) and cyclooxygenase (COX)-2 were expressed in FMS-1 cells. To improve the highly aggressive course and poor prognosis and establish new therapeutic methods, molecular genetic and biological characterizations of MPNST are required. Thus, FMS-1 cells might be useful for investigating biological behaviors and developing new molecular-targeting antitumor drugs for MPNST expressing EGFR or COX-2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19921253     DOI: 10.1007/s00428-009-0848-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  46 in total

Review 1.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

2.  Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors.

Authors:  S Birindelli; F Perrone; M Oggionni; C Lavarino; B Pasini; B Vergani; G N Ranzani; M A Pierotti; S Pilotti
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

3.  Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.

Authors:  Takahiro Naruse; Yoshihiro Nishida; Kozo Hosono; Naoki Ishiguro
Journal:  Carcinogenesis       Date:  2005-10-11       Impact factor: 4.944

4.  Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Yasuhiko Kaneko; Naoki Watanabe; Shinichi Kikuchi; Masafumi Abe
Journal:  Oncol Rep       Date:  2006-08       Impact factor: 3.906

Review 5.  Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.

Authors:  Steven L Carroll; Mark S Stonecypher
Journal:  J Neuropathol Exp Neurol       Date:  2004-11       Impact factor: 3.685

6.  Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization.

Authors:  Mikiko Aoki; Kazuki Nabeshima; Jun Nishio; Masako Ishiguro; Chikako Fujita; Kaori Koga; Makoto Hamasaki; Yasuhiko Kaneko; Hiroshi Iwasaki
Journal:  Int J Oncol       Date:  2006-12       Impact factor: 5.650

7.  Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

Review 8.  Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Authors:  Stephen Gately; William W Li
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

9.  Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.

Authors:  Hussein Tawbi; Dafydd Thomas; David R Lucas; J Sybil Biermann; Scott M Schuetze; Anita L Hart; Rashmi Chugh; Laurence H Baker
Journal:  Oncologist       Date:  2008-04

10.  Amphiregulin and epidermal growth factor receptor expression in human malignant fibrous histiocytoma of soft tissues.

Authors:  Tetsuji Yamamoto; Ikuo Fujita; Toshihiro Akisue; Takashi Marui; Tetsuya Nakatani; Teruya Kawamoto; Toshiaki Hitora; Keiko Nagira; Keiji Matsumoto; Masahiro Kurosaka
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

View more
  9 in total

1.  Explant culture of sarcoma patients' tissue.

Authors:  Roman Muff; Sander M Botter; Knut Husmann; Joelle Tchinda; Philomina Selvam; Franziska Seeli-Maduz; Bruno Fuchs
Journal:  Lab Invest       Date:  2016-04-25       Impact factor: 5.662

2.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

3.  Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells.

Authors:  Michiyuki Hakozaki; Takahiro Tajino; Shinichi Konno; Shinichi Kikuchi; Hitoshi Yamada; Michiro Yanagisawa; Jun Nishida; Hiroyuki Nagasawa; Takashi Tsuchiya; Akira Ogose; Masafumi Abe; Hiroshi Hojo
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

Review 4.  Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.

Authors:  AeRang Kim; Douglas R Stewart; Karlyne M Reilly; David Viskochil; Markku M Miettinen; Brigitte C Widemann
Journal:  Sarcoma       Date:  2017-05-16

5.  Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.

Authors:  Suguru Fukushima; Makoto Endo; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Tomoya Matsunobu; Ken-Ichi Kawaguchi; Nokitaka Setsu; Keiichiro IIda; Nobuhiko Yokoyama; Makoto Nakagawa; Kenichiro Yahiro; Yoshinao Oda; Yukihide Iwamoto; Yasuharu Nakashima
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

6.  lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.

Authors:  Hideharu Yamada; Masanobu Takahashi; Munenori Watanuki; Mika Watanabe; Sakura Hiraide; Ken Saijo; Keigo Komine; Chikashi Ishioka
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

Review 7.  Malignant peripheral nerve sheath tumor: models, biology, and translation.

Authors:  Bandarigoda N Somatilaka; Ali Sadek; Renee M McKay; Lu Q Le
Journal:  Oncogene       Date:  2022-04-07       Impact factor: 8.756

8.  Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.

Authors:  Jun Ohishi; Mikiko Aoki; Kazuki Nabeshima; Junji Suzumiya; Tamotsu Takeuchi; Akira Ogose; Michiyuki Hakozaki; Yuichi Yamashita; Hiroshi Iwasaki
Journal:  BMC Cancer       Date:  2013-05-04       Impact factor: 4.430

Review 9.  The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Xiyuan Zhang; Béga Murray; George Mo; Jack F Shern
Journal:  Genes (Basel)       Date:  2020-03-09       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.